Non-Invasive: only 5 mL maternal peripheral blood is needed. Therefore, there is no risk of intrauterine infection and miscarriage.
Highly Accurate: 100% sensitivity and 99.9% specificity.
Early-Test: can be performed at the early pregnancy (~12 weeks), which allows early detection for a better clinical decision.
Report: available within 2 weeks.
Inclusivity: All chromosomal aneuploidies could be detected in one test.
Those that wish to have non-invasive fetal aneuploidies test for trisomy21, 18 and 13.
Those whose age is 35 or above and does not choose to receive invasive prenatal tests.
Those whose serum biochemical tests and ultrasound examinations suggest high risk of chromosome aneuploidies at the first and second trimester.
Those that has contraindication of invasive prenatal testing, such as placenta previa, risks of miscarriage, HBV infection and HIV infection, etc.
Those that received IVF, or previously suffered from habitual abortion.